Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
M Croft, S Salek-Ardakani, CF Ware - Nature Reviews Drug Discovery, 2024 - nature.com
The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade),
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges
Immunotherapy is amongst the most promising new treatment modalities to arise over the
last two decades; antibody drugs are delivering immunotherapy to millions of patients with …
last two decades; antibody drugs are delivering immunotherapy to millions of patients with …
[HTML][HTML] Targeting GITR in cancer immunotherapy–there is no perfect knowledge
D Davar, R Zappasodi - Oncotarget, 2023 - ncbi.nlm.nih.gov
Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily
(TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed …
(TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed …
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
AM Tsimberidou, FA Alayli, K Okrah… - Journal of Experimental …, 2024 - rupress.org
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors
(ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various …
(ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various …
[HTML][HTML] Recent advances in immunotherapy-involved combination cancer therapy based on ZIF-8
G Wang, L Li, J Wang, C Liu, C Li, X Zheng - AIP Advances, 2024 - pubs.aip.org
This paper introduces and briefly describes the tumor immune cycle to clarify the action
mechanisms and principles of classical immunotherapy. We then focus on the classification …
mechanisms and principles of classical immunotherapy. We then focus on the classification …